ScienceOpen: research and publishing network

For Researchers

Search
Advanced search

0

views

    

0

recommends

0

shares

Record: found
Abstract: found
Article: not found

Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients.

Author(s): Konstantinos Porpodis, Kalliopi Domvri, Paul Zarogoulidis, Dimitrios Petridis, Katerina Tsirgogianni, Antonis Papaioannou, Olga Hatzizisi, Ioannis Kioumis, Alexandra Liaka, Violeta Kikidaki, Sofia Lampaki, John Organtzis, Konstantinos Zarogoulidis

Publication date: 2015

Journal: International Journal of Chronic Obstructive Pulmonary Disease

Publisher: Informa UK Ltd.

Keywords: roflumilast, COPD, phosphodiesterase-4 inhibitors

Read this article at

ScienceOpenPublisher PMC

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

A new approach to the treatment of COPD includes controlling inflammation because of its important role in exacerbation of the disease. Recently, roflumilast has been added as a therapeutic option for COPD. Roflumilast is an oral phosphodiesterase-4 inhibitor that targets inflammatory cells involved in triggering exacerbations of COPD. The objective of the current study was to evaluate roflumilast for its contribution to phagocytic activity in COPD patients.

Related collections

Author and article information

Journal

PubMed ID:: 26109853

PMC ID:: 4474389

DOI:: 10.2147/COPD.S83205

Keywords: roflumilast,COPD,phosphodiesterase-4 inhibitors

Data availability:

Keywords: roflumilast, COPD, phosphodiesterase-4 inhibitors

Comments

Comment on this article

scite_